Does Gemtesa cause high blood pressure?

Cognitive decline, which may include dementia, memory loss and confusion, is not a known side effect for Gemtesa (vibegron) or the beta-3 agonist class as a whole. In addition, a study found the use of anticholinergic medications among patients with overactive bladder (OAB) was associated with an increased risk of new-onset dementia compared to beta-3 agonist users. Continue reading

Gemtesa (vibegron) starts working almost immediately – within a few days of first taking it, with noticeable improvements in urinary urgency, frequency, and incontinence noted in clinical trials at 2 weeks which were reported as significant by 12 weeks.

After 12 weeks, people taking Gemtesa had 2 fewer daily leakage episodes compared to 1 fewer episode in those taking placebo, 2 fewer bathroom visits (versus 1 fewer with placebo), and 3 fewer “urge to go” visits a day compared to 2 fewer with placebo. Continue reading

Gemtesa (vibegron) works by relaxing the detrusor muscle of the bladder – this is smooth muscle found in the wall of the bladder – and it does this by activating beta-3 adrenergic receptors located in the detrusor muscle. By activating these receptors, the muscle in the bladder wall relaxes. This allows the bladder to hold more urine, which can relieve symptoms of overactive bladder such as needing to pass urine immediately or frequently (urinary urgency and frequency) and reduce urine leakage (urinary incontinence). Continue reading